ROCKVILLE, Md., Oct. 15, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:
Chardan's 9th Annual Genetic Medicines Conference
Panel "Battleground States for Muscular Dystrophies": Tuesday, October 21 at 2:00 p.m. ET
Panel "CNS GT – Lessons from Mature Programs & the Field's Next Frontiers": Tuesday, October 21 at 2:45 p.m. ET
Location: New York, NY
Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Fireside Chat: Monday, November 10, 2025 at 9:00 a.m. ET
Location: Boston, MA
Stifel 2025 Healthcare Conference
Fireside Chat: Tuesday, November 11, 2025 at 1:20 p.m. ET
Location: New York, NY
Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. Archived replays of the webcasts will be available for approximately 30 days following the events.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
George E. MacDougall
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$11.56 |
| Daily Change: | -0.43 -3.59 |
| Daily Volume: | 605,969 |
| Market Cap: | US$583.900M |
October 30, 2025 October 09, 2025 October 06, 2025 September 29, 2025 September 05, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
